PBLA stock is a buy, Roth says : comparemela.com

Following some good news for the company, Roth MKM analyst Jonathan Aschoff has maintained his “Buy” rating on Panbela Therapeutics.

Related Keywords

Jenniferk Simpson , Jonathan Aschoff , , Panbela Therapeutics , Panbela Therapeutics Stock Quote , Financials Nasdaq , Data Safety Monitoring Board ,